The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

CAR-T cell therapy provides long, treatment-free remissions for relapsed multiple myeloma, using genetically modified T cells ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

A blood cancer diagnosis comes with a lot of new information and confusion ranging from blood tests and medical terminology to healthcare provider conversations and treatment considerations. Here’s ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...